Clinical trial
A Multicenter, Prospective, Real-world Study Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology
NCT07161453 is registered in ClinicalTrials.gov with Liaoning Cancer Hospital & Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Prospective, Real-world Study Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology
- Lead sponsor
- Liaoning Cancer Hospital & Institute
- Phase
- Phase 4
- Overall status
- Not yet recruiting
- Start date
- September 30, 2025
- Completion date
- December 31, 2027
- Enrollment
- 500 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
gastric / gastroesophageal junction adenocarcinoma